Skip to main content

Almost 600,000 in England awaiting gynaecological treatment, figures show

Exclusive: analysis shows increase of a third in two years, prompting claim of ‘deprioritising women’s health’

The government has been accused of “deprioritising women’s health” as analysis shows that almost 600,000 women in England are waiting for gynaecological treatment, an increase of a third over two years.

There are 33,000 women waiting more than a year for such treatment, an increase of 43%, according to Labour analysis of data from the House of Commons library.

Continue reading...

from The Guardian https://ift.tt/EDTKj4p
Labels:

Comments

Post a Comment

Popular posts from this blog

England booed off after failing against Iceland once more in Euros warm-up

It was a long way from being the triumphant Euro 2024 send-off for Gareth Southgate and his England players at a sold-out and increasingly fretful Wembley. Never mind the result because it was not the main thing, however much it stirred memories of you-know-when against Iceland. It was the performance that raised the difficult questions, the worst one for quite some time and at exactly the wrong time. The home fans, thousands of whom made for the exits before the end, were forced to watch the second half – from about minute 55 onwards – through the gaps between their fingers. And it had not been great before that. Continue reading... from The Guardian https://ift.tt/4ndfQL0
Post a Comment
Read more

Trump to campaign in 4 states - including in Biden's hometown - during week of Democratic National Convention

Trump plans to hold a series of events next week in Pennsylvania, Wisconsin, Minnesota and Arizona as Democrats nominate Joe Biden for president.             from USATODAY - News Top Stories https://ift.tt/3al6qn7
Post a Comment
Read more

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca | Nils Prately

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere Is Pascal Soriot, the chief executive of AstraZeneca, “massively underpaid”, as the chief investment officer of Florida-based GQG Partners, one of the company’s big shareholders, argued this week? Well, of course he’s not. Soriot has been paid £120m over the past decade, which is a helluva sum even for someone who has been brilliantly successful in leading what is now – but wasn’t when he arrived – the UK’s second-largest listed company. The history-turning moment in 2014, when AZ and Soriot managed to see off a bid from Pfizer’s grim number-crunchers, has probably been worth many multiples of £120m to the UK economy. But such a sum for a single employee in an organisation of 90,000 still looks absurd: Soriot doesn’t do all the work himself. Continue reading... from The Guardian https://ift.tt/V2FnCkM
Post a Comment
Read more